Sadhana Jackson, M.D.

Sadhana Jackson, M.D.
Adjunct Investigator
Investigator, Surgical Neurology Branch, NINDS

Dr. Jackson’s research interests center on evaluating the blood-brain barrier (BBB) of malignant gliomas.  Her clinical and translational research focuses on transiently disrupting the BBB by pharmacologic means, in an effort to improve cytotoxic therapy to the central nervous system.  She uses brain microdialysis, pharmacokinetic analysis, and preclinical models to study central nervous system (CNS) pharmacology. Dr. Jackson also leads collaborative preclinical and clinical studies focused on understanding BBB integrity in normal brain and malignant gliomas with the goal of developing novel treatment strategies for brain tumor patients.

Dr. Jackson is an Adjunct Investigator in CCR's Pediatric Oncology Branch.

Areas of Expertise

1) neuro-oncology, 2) blood-brain barrier, 3) drug delivery, 4) pharmacokinetics, 5) malignant brain tumors

Contact Info

Sadhana Jackson, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 7D45
Bethesda, MD 20892
Ph: 301-594-7037

One of the major obstacles to effectively treating central nervous system (CNS) tumors is the integrity of the blood-brain barrier (BBB). The BBB prevents systemic drug delivery from reaching the brain and brain tumor tissue. While previous studies have mainly focused on circumventing the BBB, very few agents or mechanisms have been explored that modulate the tumor microenvironment to enhance effective therapies for malignant brain tumors.

Dr. Jackson's studies focus on understanding the heterogeneity of BBB permeability amongst malignant tumor cells and the role of the supportive BBB in tumor growth. Her collaborative laboratory and clinical investigations center around BBB biology, cancer biology, pharmacokinetics and pharmacodynamics related to optimal CNS drug delivery.

NIH Scientific Focus Areas:
Clinical Research
View Dr. Jackson's PubMed Summary.

Selected Recent Publications

  1. Jackson S, Meeks C, Vézina A, Robey RW, Tanner K, Gottesman MM.
    Biomaterials. 214: 119217, 2019. [ Journal Article ]
  2. Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA.
    Fluids Barriers CNS. 15(1): 2, 2018. [ Journal Article ]
  3. Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA.
    J Neurooncol. 132(3): 513-519, 2017. [ Journal Article ]
  4. McCord M, Mukouyama YS, Gilbert MR, Jackson S.
    Front Cell Neurosci. 11: 318, 2017. [ Journal Article ]
  5. Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, Brem H, Tyler B, Rudek MA, Grossman SA.
    J Neurooncol. 126(3): 433-9, 2016. [ Journal Article ]

Dr. Jackson attended Hampton University where she received her Bachelor of Science in Molecular Biology. She then obtained her M.D. from Eastern Virginia Medical School (EVMS). Dr. Jackson subsequently completed a residency in Pediatrics at Orlando Health and afterwards completed her pediatric hematology/oncology fellowship at St. Jude Children’s Research Hospital. Additionally, she completed a joint pediatric neuro-oncology and clinical pharmacology fellowship at Johns Hopkins Medical Institute before being selected as an NCI Assistant Clinical Investigator in the Clinical Investigator Development Program in 2015.

Dr. Sadhana Jackson is a board-certified pediatrician and pediatric hematologist/oncologist with clinical expertise and research efforts related to the blood-brain barrier and malignant gliomas. Dr. Jackson’s clinical practice focuses on drug delivery of systemic agents for pediatric malignant brain tumor patients. She has extensive experience with use of intracerebral microdialysis and intratumoral/peritumoral pharmacology to evaluate optimal drug entry in malignant brain tumors.